CAVectors for Targeted Genetic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective delivery vehicles for genetic material and therapeutic agents into mammalian and avian cells, particularly for targeting specific cellular functions and treating diseases with minimal integration into the host genome.
Innovation Solution
Development of CAVectors, which are synthetic or modified chicken anemia virus particles encapsulating genetic elements with high sequence identity to CAV sequences, equipped with a proteinaceous exterior for targeted delivery and minimal integration into eukaryotic cells, allowing for therapeutic agent delivery and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery vehicles are used to deliver genetic material and therapeutic agents, then delivery capability is achieved, but targeted delivery to specific cellular functions and minimal genomic integration are not realized
Solution Approach 1:
The patent extracts the capsid protein VP1 from the natural CAV virus and uses it to form synthetic capsids that encapsulate therapeutic genetic material. This extraction allows the delivery vehicle to be created without the harmful viral genome, achieving targeted delivery while eliminating the risk of genomic integration and viral replication.
Solution Approach 2:
The patent creates synthetic copies of the CAV capsid structure using the VP1 protein, forming capsids that mimic the natural virus architecture but lack the viral genome. These synthetic capsids serve as delivery vehicles that replicate the protective and delivery functions of the natural virus without causing harmful integration into the host genome.
2Manufacturing precision
If synthetic CAVectors are developed with proteinaceous exterior for targeted delivery, then delivery specificity is improved, but manufacturing complexity increases
Solution Approach 1:
The synthetic capsids self-assemble around the encapsulated genetic material through spontaneous assembly of VP1 protein subunits. This self-assembly process eliminates the need for complex manual assembly procedures, reducing manufacturing complexity while maintaining high delivery targeting accuracy through the inherent structural properties of the capsid.
Solution Approach 2:
The patent modifies the VP1 protein sequence to create variants with improved stability and delivery characteristics. By changing parameters such as amino acid sequences and capsid structure, the system achieves enhanced targeting accuracy while maintaining manufacturability through standardized protein expression and assembly protocols.
3Productivity
If CAVectors are used to deliver therapeutic agents, then therapeutic efficacy is enhanced, but risk of off-target effects increases
Solution Approach 1:
The patent incorporates specific targeting sequences and structural features in the capsid that enable localized delivery to specific cell types and tissues. The capsid structure and surface properties are optimized to interact with specific cellular receptors, ensuring that the therapeutic agents are delivered only to the intended target cells, thereby enhancing therapeutic efficacy while minimizing off-target effects.
Data Source
AI summary
This invention relates generally to compositions for making C A Vectors and uses thereof.